Medicare could require Biogen, Inc. and Eisai Co., Ltd. to collect clinical data on the use and effectiveness of aducanumab in Alzheimer’s disease as a condition of coverage if the drug is approved by the US Food and Drug Administration.
Coverage with evidence development offers a way for Medicare to manage aducanumab’s high potential cost in light of questions that...







